Aesthetic plastic surgery · 2026
Computational Trial of Prophylactic Biostimulator Interventions to Mitigate Facial Sagging Associated With GLP-1 Receptor Agonist Induced Weight Loss.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rahman Eqram, Michon Alain, Rao Parinitha, Saklayen Golam, Ahmed Munim, Joseph John H, Wu Woffles T L, Webb William Richard
Аннотация
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide induce rapid weight loss, including facial adipose reduction, which may accelerate sagging due to loss of soft-tissue support. Preventive strategies remain unvalidated, and prospective trials are challenging.
OBJECTIVE: To evaluate in silico whether prophylactic injectable treatments along lateral facial vectors mitigate sagging during one year of semaglutide-associated weight loss and compare efficacy across product classes.
METHODS: A large-scale virtual randomized trial was conducted using the AESTHETISIM™ platform. A total of 12,000 digital twins (adults aged 30-50, BMI >30 kg/m2) were randomized into six arms: control, hyaluronic acid (HA), hyperdiluted calcium hydroxylapatite (CaHA), hybrid HA+CaHA, poly-L-lactic acid (PLLA), and a bio-remodelling injectable. All received simulated semaglutide exposure. A finite-element biomechanical model incorporated compartment-specific fat loss, gravitational loading, ligament support, and time-dependent dermal adaptation. The primary endpoint was a facial sagging index (FSI) based on inferior landmark displacement; secondary endpoints included midface descent and jawline curvature. Bayesian hierarchical models provided comparative inference.
RESULTS: All prophylactic injectable strategies reduced facial sagging relative to control (posterior probability >0.99). At 12 months, CaHA achieved the greatest reduction in facial sagging index (ΔFSI -2.74 mm), followed by HA+CaHA (-2.60 mm) and the bio-remodelling injectable (-2.41 mm). Hyaluronic acid demonstrated a strong early effect with subsequent attenuation (-1.11 mm), whereas poly-L-lactic acid showed a delayed and modest benefit within the one-year horizon (-1.30 mm). Mechanistic analyses indicated that durable sagging prevention was driven primarily by increased resistance to creep and redistribution of lateral facial loads rather than transient volumization. An exploratory multi-session sensitivity analysis showed that a second prophylactic session produced modest late-phase improvement for slower-acting agents, particularly poly-L-lactic acid (additional ≈0.5 mm reduction in facial sagging index at 12 months), without altering the overall one-year superiority of CaHA-based strategies.
CONCLUSIONS: Prophylactic lateral-vector injectables reduced facial sagging in this virtual trial. Within the modelled parameter space, CaHA-based strategies predicted the greatest one-year protection. PLLA's delayed action may be underrepresented in single-session designs. These findings provide proof-of-concept support for preventive aesthetic approaches in GLP-1 RA patients and generate testable hypotheses requiring prospective clinical validation. The comparative rankings observed should be interpreted as model-derived predictions contingent on underlying parameter assumptions rather than definitive clinical evidence.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
OBJECTIVE: To evaluate in silico whether prophylactic injectable treatments along lateral facial vectors mitigate sagging during one year of semaglutide-associated weight loss and compare efficacy across product classes.
METHODS: A large-scale virtual randomized trial was conducted using the AESTHETISIM™ platform. A total of 12,000 digital twins (adults aged 30-50, BMI >30 kg/m2) were randomized into six arms: control, hyaluronic acid (HA), hyperdiluted calcium hydroxylapatite (CaHA), hybrid HA+CaHA, poly-L-lactic acid (PLLA), and a bio-remodelling injectable. All received simulated semaglutide exposure. A finite-element biomechanical model incorporated compartment-specific fat loss, gravitational loading, ligament support, and time-dependent dermal adaptation. The primary endpoint was a facial sagging index (FSI) based on inferior landmark displacement; secondary endpoints included midface descent and jawline curvature. Bayesian hierarchical models provided comparative inference.
RESULTS: All prophylactic injectable strategies reduced facial sagging relative to control (posterior probability >0.99). At 12 months, CaHA achieved the greatest reduction in facial sagging index (ΔFSI -2.74 mm), followed by HA+CaHA (-2.60 mm) and the bio-remodelling injectable (-2.41 mm). Hyaluronic acid demonstrated a strong early effect with subsequent attenuation (-1.11 mm), whereas poly-L-lactic acid showed a delayed and modest benefit within the one-year horizon (-1.30 mm). Mechanistic analyses indicated that durable sagging prevention was driven primarily by increased resistance to creep and redistribution of lateral facial loads rather than transient volumization. An exploratory multi-session sensitivity analysis showed that a second prophylactic session produced modest late-phase improvement for slower-acting agents, particularly poly-L-lactic acid (additional ≈0.5 mm reduction in facial sagging index at 12 months), without altering the overall one-year superiority of CaHA-based strategies.
CONCLUSIONS: Prophylactic lateral-vector injectables reduced facial sagging in this virtual trial. Within the modelled parameter space, CaHA-based strategies predicted the greatest one-year protection. PLLA's delayed action may be underrepresented in single-session designs. These findings provide proof-of-concept support for preventive aesthetic approaches in GLP-1 RA patients and generate testable hypotheses requiring prospective clinical validation. The comparative rankings observed should be interpreted as model-derived predictions contingent on underlying parameter assumptions rather than definitive clinical evidence.
LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .